ImClone Systems, Inc. (IMCL)

CAPS Rating:

A biopharmaceutical company which advances oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers.

View All Commentary (IMCL)

Recs

6

Avatar TMFPeterJ (< 20) Submitted: 8/28/06 5:14 PM : Start Price: $34.94 IMCL Score: -6.02

You hate to vote against stock in a company doing something as vital as cancer research. But IMCL's track record suggests its research could produce better results in the hands of a more well-run biotech.

Report this Post Replies: 2 | Reply

Avatar hazar154 (98.44) Submitted: 1/26/07 4:28 AM

Recs: 0 | Rec This

Well, I know I am going against the flow here, but I believe that, although the management sucks, the prejudice against Erby is incredible. Last two weeks were interesting: Erby meets endpoint in 1st line -- "very robust results" according to cc, to be presented soon. Yesterday AMGN discloses comparison between Avastin chemo group compared to Avastin chemo Vectibix group: no improvement with Vectibix, only diarrhea. Head and neck PIII for Vectibix postponed. First line metastatic PIII deffered to improve study design.
I somehow feel that many observers (including Charly, if I'm not mistaken) were too quick to bet on the success of Vectibix, and they did this even before results were announced.

Report this Post Reply

Avatar AnomaLee (99.49) Submitted: 1/22/08 3:48 PM

Recs: 0 | Rec This

I agree, but I'm thinking/hoping that the conference call on Jan 31 will be quite positive.

Report this Post Reply

ImClone Systems, Inc. (IMCL)

6

Featured Broker Partners